Seeking Alpha's "The Undercovered Dozen" is a weekly series that spotlights 12 lesser-covered stocks with market caps over $100 million and limited recent coverage. The series aims to introduce investors to overlooked investment opportunities, encouraging community discussion and further research. It includes a mix of large and small cap stocks that meet specific criteria for undercoverage. This initiative helps investors discover unique stocks that might be worth adding to their portfolios.
Bunzl PLC reported stronger-than-expected financial results with an EPS of $0.60, surpassing the $0.56 consensus. Revenue reached $8.04 billion, driven by a 3.2% underlying growth, especially in North America. The operating margin improved to 7.3%, p...
Palo Alto Networks is set to report strong earnings per share (EPS) of $0.98 and revenue of $3.35 billion for the upcoming quarter, reflecting significant growth from last year. Investor optimism is driven by robust cybersecurity sector trends and a ...
Medtronic reported Q3 earnings per share of $1.45, surpassing estimates of $1.39, and revenue of $9.76 billion, above the $9.55 billion consensus. The strong financial results reflect broad demand for its cardiovascular devices. The company raised it...
Dell Technologies is expected to report record second-quarter earnings with EPS around $4.91 and revenue near $44.89 billion, fueled by high demand for its AI-optimized servers. This would mark a significant increase from last year's $29.78 billion a...
Protagonist Therapeutics saw its stock price target raised to $180 by Barclays following the FDA approval of MIMRYLO, a first-in-class drug for polycythemia vera. The approval was based on strong Phase 3 trial results with 76.9% patient response, tri...
